<unk>  is an issue that occurs in women who are at risk for clot formation and subsequently become pregnant.  While the general consensus among physicians is that the safety of the mother supersedes the safety of the developing fetus, changes in the<unk>  regimen during<unk>  can be performed to minimize the risks to the developing fetus while maintaining therapeutic levels of<unk>  in the mother.
The main issue with<unk>  is that warfarin, the most commonly used anticoagulant in chronic administration, is known to have teratogenic effects on the fetus if administered in early<unk> .
Anticoagulation in pregnancy
High risk pregnancy
Cardiac disease in pregnancy
Immunization during pregnancy
Antiphospholipid syndrome risk factors
Aortic dissection management during pregnancy
Pre-eclampsia risk factors
Antiphospholipid syndrome medical therapy